Total Payments
$6,414
2024 Payments
$373.02
Companies
27
Transactions
395
Medicare Patients
24
Medicare Billing
$833.05
Payment Breakdown by Category
Food & Beverage$6,268 (97.7%)
Education$146.27 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,268 | 384 | 97.7% |
| Education | $146.27 | 11 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $1,282 | 89 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $1,193 | 89 | $0 (2024) |
| Ironshore Pharmaceuticals Inc. | $651.97 | 16 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $625.80 | 44 | $0 (2023) |
| Supernus Pharmaceuticals, Inc. | $475.28 | 29 | $0 (2023) |
| Alkermes, Inc. | $358.35 | 17 | $0 (2022) |
| Allergan, Inc. | $319.70 | 27 | $0 (2020) |
| Vanda Pharmaceuticals Inc. | $296.67 | 11 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $187.82 | 12 | $0 (2022) |
| Tris Pharma Inc | $168.02 | 11 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $373.02 | 3 | E.R. Squibb & Sons, L.L.C. ($126.24) |
| 2023 | $176.46 | 10 | Supernus Pharmaceuticals, Inc. ($90.08) |
| 2022 | $816.50 | 46 | Supernus Pharmaceuticals, Inc. ($253.79) |
| 2021 | $192.67 | 13 | Supernus Pharmaceuticals, Inc. ($131.41) |
| 2020 | $407.62 | 23 | Ironshore Pharmaceuticals Inc. ($86.99) |
| 2019 | $1,895 | 116 | Ironshore Pharmaceuticals Inc. ($548.36) |
| 2018 | $1,556 | 114 | Sunovion Pharmaceuticals Inc. ($385.60) |
| 2017 | $996.87 | 70 | Otsuka America Pharmaceutical, Inc. ($354.07) |
All Payment Transactions
395 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/25/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | Cash or cash equivalent | $124.97 | General |
| Category: SCHIZOPHRENIA | ||||||
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $126.24 | General |
| 04/09/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Food and Beverage | In-kind items and services | $121.81 | General |
| Category: PSYCHIATRY | ||||||
| 09/07/2023 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $19.75 | General |
| Category: PSYCHOLOGY | ||||||
| 04/18/2023 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $18.32 | General |
| Category: PSYCHOLOGY | ||||||
| 04/14/2023 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $23.23 | General |
| Category: PSYCHOLOGY | ||||||
| 02/09/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: PSYCHIATRY | ||||||
| 02/02/2023 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: PSYCHIATRY | ||||||
| 01/26/2023 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $15.32 | General |
| Category: PSYCHOLOGY | ||||||
| 01/20/2023 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $18.09 | General |
| Category: PSYCHIATRY | ||||||
| 01/17/2023 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $13.46 | General |
| Category: PSYCHOLOGY | ||||||
| 01/06/2023 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: Neuroscience | ||||||
| 01/03/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: PSYCHIATRY | ||||||
| 12/21/2022 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA INITIO | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: CNS | ||||||
| 12/15/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $11.85 | General |
| Category: PSYCHOLOGY | ||||||
| 12/06/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $8.64 | General |
| Category: PSYCHOLOGY | ||||||
| 12/01/2022 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA, INVEGA | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: Neuroscience | ||||||
| 11/29/2022 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: PSYCHIATRY | ||||||
| 11/22/2022 | Merck Sharp & Dohme LLC | BELSOMRA (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: NEUROSCIENCE | ||||||
| 11/17/2022 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA, INVEGA | Food and Beverage | In-kind items and services | $21.72 | General |
| Category: Neuroscience | ||||||
| 11/16/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $7.09 | General |
| Category: PSYCHOLOGY | ||||||
| 11/15/2022 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $18.51 | General |
| Category: Psychology/Psychiatric | ||||||
| 11/10/2022 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: CNS | ||||||
| 11/10/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $19.71 | General |
| Category: PSYCHOLOGY | ||||||
| 11/02/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $7.27 | General |
| Category: PSYCHOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 1 | 24 | 24 | $3,126 | $833.05 |
Total Patients
24
Total Services
24
Medicare Billing
$833.05
Procedure Codes
1
All Medicare Procedures & Services
1 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 24 | 24 | $3,126 | $833.05 | 26.6% |
About Dr. Michael Kent, MD
Dr. Michael Kent, MD is a Neurology healthcare provider based in Wentzville, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174607071.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Kent, MD has received a total of $6,414 in payments from pharmaceutical and medical device companies, with $373.02 received in 2024. These payments were reported across 395 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($6,268).
As a Medicare-enrolled provider, Kent has provided services to 24 Medicare beneficiaries, totaling 24 services with total Medicare billing of $833.05. Data is available for 1 year (2020–2020), covering 1 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Child & Adolescent Psychiatry
- Location Wentzville, MO
- Active Since 10/25/2006
- Last Updated 03/26/2019
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1174607071
Products in Payments
- LATUDA (Drug) $1,270
- REXULTI (Drug) $648.19
- ABILIFY MAINTENA (Drug) $576.97
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $548.36
- QELBREE (Drug) $475.28
- VRAYLAR (Drug) $312.12
- INVEGA SUSTENNA (Drug) $271.78
- Aristada 441 mg (Drug) $227.53
- INGREZZA (Drug) $187.82
- SPRAVATO (Drug) $174.88
- INVEGA TRINZA (Drug) $156.32
- Dyanavel XR (Drug) $154.73
- Adzenys XR-ODT (Drug) $151.97
- Fanapt (Drug) $125.62
- FANAPT (Drug) $124.97
- ARISTADA (Drug) $115.37
- JORNAY PM (Drug) $103.61
- MYDAYIS (Drug) $80.59
- VYVANSE (Drug) $77.75
- Aptensio XR (Drug) $70.64
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.